Aarti pharma labs has received a single procedural Form 483 observation from the US Food and Drug Administration (FDA) following an inspection of its Tarapur Unit-IV manufacturing facility that concluded on March 27, 2026. The company has formally disclosed this development to stock exchanges under Regulation 30 of SEBI regulations and confirmed its commitment to address the regulatory requirement through timely submission of its Corrective and Preventive Action (CAPA) response.

FDA Inspection Outcome

The FDA inspection of the Tarapur Unit-IV facility, located at Plot No. E-50, 50/1, 59/1, MIDC, Tarapur, Tal. & District Palghar, Maharashtra, resulted in one procedural observation documented through Form 483. This regulatory document is issued by FDA inspectors when they identify conditions or practices that may constitute violations of FDA regulations during facility inspections.

Regulatory Disclosure and Company Response

Aarti Pharmalabs has formally notified BSE Limited and National Stock Exchange of India Limited about the inspection outcome through an official communication signed by Company Secretary and Legal Head Jeevan Mondkar. The company has indicated its intention to file the required CAPA documentation within the prescribed timeline, addressing the corrective and preventive actions for the observation along with compliance submission to the US FDA.

Regulatory Context

Form 483 observations are standard regulatory communications that pharmaceutical companies receive following FDA inspections. Companies typically have a stipulated period to respond to these observations with detailed plans for addressing the identified issues. The procedural nature of this observation suggests it relates to documentation or process compliance rather than product quality concerns, maintaining the facility's operational status while requiring administrative corrections.

Aarti Pharmalabs Limited reported a minor chemical leak incident at its Unit-VI facility in Tarapur on March 22, disclosing the event under Regulation 30 of SEBI (LODR) Regulations, 2015. The pharmaceutical company took immediate precautionary measures to ensure employee safety and contain the situation.

Incident Details and Chemical Involved

The incident occurred during the loading of dimethyl sulphate, a low-cost industrial chemical, into a tanker at the company's Unit-VI facility located at Plot No. D-18, MIDC, Tarapur, Tal. & Dist.- Palghar. The minor leakage was cleared immediately following standard safety protocols.

Safety Response and Medical Care

Following the chemical leak, the company promptly sent 22 workers to a local hospital for precautionary observation. More than half of the affected employees have already been discharged, demonstrating the minor nature of the incident and effective medical response.

Regulatory Compliance and Investigation

Aarti Pharmalabs informed the local police station about the incident, and a FIR has been registered as per standard procedures. The investigation process is currently ongoing, with the company committing to full cooperation with investigation agencies.

Operational Recovery

Normal plant operations were safely restored within 24 hours of the incident, indicating effective containment and minimal operational disruption. The quick resumption of activities demonstrates the company's operational resilience and emergency response capabilities. No loss of life or damage to property was reported, confirming the effectiveness of immediate safety measures implemented at the site.